{"filings":[{"id":1485756,"accession_number":"0001193125-26-297085","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-07-07T14:38:16+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Semnur signs binding term sheet for $100M strategic investment from iHolding Group at $10/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iHolding to purchase $100M of newly issued common stock at $10/share (~10M shares).","Proceeds to fund SEMDEXA Phase 3 program, product development, acquisitions, working capital.","Investment subject to due diligence, definitive agreements, board/stockholder/regulatory approvals.","Semnur is a majority-owned subsidiary of Scilex Holding Company.","No assurance of consummation; risks of termination or litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1278877,"accession_number":"0001193125-26-283007","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-06-25T21:03:49+00:00","items":["5.07","9.01"],"status":"ready","headline":"Semnur stockholders elect director, ratify auditor, approve 2025 equity plans at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jay Chun, M.D., Ph.D. elected Class I director with 200,166,258 for, 3,804 withheld, 137,409 broker non-votes.","Ratification of Pipara & Co LLP as auditor for FY 2026: 200,307,425 for, 46 against, 0 abstentions.","2025 Equity Incentive Plan approved: 200,166,256 for, 269 against, 3,537 abstentions, 137,409 broker non-votes.","2025 Employee Stock Purchase Plan approved: 200,166,255 for, 270 against, 3,537 abstentions, 137,409 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96704,"accession_number":"0001193125-26-173690","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Semnur terminates two material financing agreements totaling $120M in potential proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated PIPE SPA with JW Capital Securities Ltd for 1.25M shares at $16/share ($20M).","Terminated Semnur/Biconomy SPA for 6.25M shares at $16/share payable in Bitcoin ($100M).","No shares were ever issued under either agreement; both terminations effective April 20, 2026.","Company delivered termination notices under Section 8 of each SPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110836,"accession_number":"0001193125-26-110816","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Jaisim Shah retires; Henry Ji appointed CEO and President; Stephen Ma named COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jaisim Shah resigned as CEO, President, and director effective March 13, 2026; retirement not due to any disagreement.","Henry Ji (age 61), formerly Executive Chairperson, appointed CEO and President; also CEO of Scilex (SCLX) and Vivasor.","Stephen Ma, previously CFO and Secretary, appointed COO effective March 17, 2026; also COO of Scilex.","Shah receives six months base salary ($1,250,000/yr) and 90-day extension to exercise vested stock options per separation agreement.","Board size reduced from six to five directors following Shah's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127458,"accession_number":"0001193125-25-306757","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Semnur Pharmaceuticals files updated securities description reflecting charter and bylaws amendments","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updates description of common stock and warrants per amendments to certificate of incorporation and bylaws since 2024 year-end.","Securities continue to trade on OTCQB under symbols SMNR and SMNRW; no change in trading status.","No material financial or operational events disclosed; filing is administrative in nature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144255,"accession_number":"0001193125-25-220455","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.01","9.01","5.02","3.02","4.01","2.03","3.03","8.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Semnur completes de-SPAC merger with Denali; trades under SMNR on OTCQB","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed Sept 22, 2025; Legacy Semnur becomes wholly owned subsidiary of New Semnur.","Exchange ratio of 1.25; SHC contributed $54.2M intercompany debt for 5.4M shares of Legacy Semnur preferred.","Entered Securities Purchase Agreement with Biconomy PTE.LTD for 6.25M shares at $16/share payable in Bitcoin.","Settled underwriter deferred discount and sponsor/futuretech debts with cash, shares, and promissory notes.","Trading symbols changed to SMNR (common) and SMNRW (warrants) on OTCQB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144254,"accession_number":"0001213900-25-084180","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve merger with Semnur Pharmaceuticals at September 3 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 proposals, including business combination with Semnur, approved by 94.08% quorum.","Domestication from Cayman Islands to Delaware and amended charter/bylaws approved.","New board of directors elected: Jaisim Shah, Henry Ji, Jay Chun, Dorman Followwill, Yue Alexander Wu.","Issuance of >20% of Denali shares and conversion of Semnur options into New Semnur options approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144253,"accession_number":"0001213900-25-079504","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Denali Capital enters $20M PIPE at $16/share and 12M share escrow for Semnur merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["PIPE purchase of 1.25M shares at $16.00 each for $20M total from a single purchaser.","Shares sold exempt under Section 4(a)(2) and Rule 506(b); restricted securities.","Semnur to deposit 12M shares of New Semnur common stock into escrow within 20 business days post-closing.","Closing conditioned on business combination; termination date for PIPE is Dec 31, 2025.","Merger agreement (amended) with Denali Merger Sub Inc. and Semnur; S-4 effective Aug 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144252,"accession_number":"0001213900-25-073907","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends SPAC deadline to Sep 11, 2025 with $874.78 trust deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend business combination deadline by one month.","Extension moves deadline from August 11, 2025 to September 11, 2025.","No business combination announced; extension provides additional time to complete a deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144251,"accession_number":"0001213900-25-068263","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.","Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.","Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.","Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144250,"accession_number":"0001213900-25-063294","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends combination deadline to Aug 11, 2025 with $874.78 deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline by one month to August 11, 2025.","Previous deadline was July 11, 2025.","Extension provides additional time to consummate initial business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162616,"accession_number":"0001213900-25-053576","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. extends business combination deadline to July 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline from June 11 to July 11, 2025.","Extension funded via convertible promissory note from Scilex Holding (SCLX) with principal up to $180,000.","Note bears no interest, convertible at $10.00/share upon business combination; remaining $56,920.74 available for future extensions.","Note repayable on earlier of business combination or liquidation of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162615,"accession_number":"0001213900-25-041653","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to June 11, 2025 with $874.78 trust deposit funded by Scilex note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $874.78 into trust account to extend deadline from May 11 to June 11, 2025.","Deposit funded by convertible promissory note from Scilex (SCLX) with principal up to $180,000, no interest.","Note convertible at Scilex's discretion into Class A shares at $10.00 per share upon business combination close.","Remaining $57,795.52 available under note expected to fund future one-month extensions if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162614,"accession_number":"0001213900-25-034254","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Denali Capital amends merger pact with Semnur; extends deadline to Sept 2025, addresses Nasdaq delisting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment allows Denali to extend business combination deadline to Dec 11, 2025, or later if mutually agreed.","Outside Date for closing merger extended to Sept 30, 2025; if extension effective, Outside Date becomes Extension Date.","Modifies covenants to address Denali's Nasdaq delisting and subsequent OTC Markets quotation of its securities.","Denali will use reasonable best efforts to list its units, shares, and warrants on OTC Markets after Nasdaq delisting.","Other changes include updating blank-check company status and proxy statement requirements for shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162613,"accession_number":"0001213900-25-032299","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.","Holders of ~708,098 Class A shares redeemed for ~$8.6M (~$12.17/share); only 43,739 Class A shares remain outstanding.","Company deposited $874.78 into trust for first extension to May 11, 2025, funded by Scilex convertible note (up to $180K).","Scilex note bears no interest, convertible at $10/share; remaining $58,670.30 available for future extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162612,"accession_number":"0001213900-25-030048","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.","Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.","Company expects to trade on OTC market after delisting; plans to remain a reporting company.","Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180612,"accession_number":"0001213900-25-022858","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to April 11 via $15K trust deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust to extend deadline from March 11 to April 11, 2025.","Funding via convertible promissory note from Scilex (SCLX) with principal up to $180,000.","Note bears no interest, convertible into Class A shares at $10.00 per share upon closing.","Remaining $59,545.08 under note available for future one-month extensions.","Company is a blank check SPAC seeking a merger or acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180611,"accession_number":"0001213900-25-012213","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. Extends Business Combination Deadline to March 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,036.74 into trust account to extend deadline for completing a business combination by one month.","Extension moves deadline from February 11, 2025 to March 11, 2025.","Funding from a convertible promissory note issued to Scilex Holding Company (SCLX) with a principal amount of up to $180,000.","Note is non-interest bearing, repayable upon business combination or liquidation, and convertible into Class A ordinary shares at $10.00 per share at Scilex's option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180610,"accession_number":"0001213900-25-002085","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to Feb 11, 2025; deposits $15k via Scilex note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust account to extend deadline from Jan 11 to Feb 11, 2025.","Extension funded via convertible promissory note from Scilex Holding Company (SCLX) with principal up to $180,000.","Note bears no interest, repayable upon business combination or liquidation; convertible at $10.00/share.","Remaining $89,672.56 available under note to fund potential future one-month extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197430,"accession_number":"0001213900-24-107941","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. extends combination deadline to Jan 11, 2025; deposits $15,064","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust account to extend deadline from Dec 11, 2024 to Jan 11, 2025.","Extension funded via convertible promissory note from Scilex Holding Company (Nasdaq: SCLX) for up to $180,000.","Note bears no interest, repayable upon business combination or liquidation; convertible at $10.00/share into Class A ordinary shares.","Remaining $104,708.30 principal available for future monthly extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197429,"accession_number":"0001213900-24-096807","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to Dec 11, 2024 with $15,064 deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust account to extend deadline from Nov 11 to Dec 11, 2024.","Funding came from a convertible promissory note issued to Scilex Holding (SCLX) for up to $180,000.","Note bears no interest, repayable upon business combination or liquidation; convertible at $10.00/share.","Remaining $119,772.04 under the note may fund future monthly extensions.","SPAC (DECA) is a blank-check company seeking a business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197428,"accession_number":"0001213900-24-087340","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. extends deadline to Nov 11, 2024 with $15,064 deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust account to extend deadline one month from Oct 11 to Nov 11, 2024.","Extension funded via convertible promissory note from Scilex Holding Company (SCLX) with up to $180,000 principal.","Note bears no interest and is convertible into DECA Class A shares at $10.00/share upon business combination close.","Remaining $134,835.78 note principal available for future one-month extensions if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197427,"accession_number":"0001213900-24-085921","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Denali Capital Acquisition receives Nasdaq deficiency notice for non-compliance with listing rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Denali on Oct 2, 2024 of non-compliance with MVLS ($50M minimum) and Total Assets rules for Nasdaq Global Market.","Company has 180 days, until March 31, 2025, to regain compliance by meeting MVLS >= $50M for 10 consecutive business days.","No immediate delisting; securities continue trading on Nasdaq; management is evaluating options to regain compliance.","Failure to comply by deadline may result in a delisting notice with opportunity to appeal to a Nasdaq Hearing Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213665,"accession_number":"0001213900-24-077790","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to Oct 11, 2024 via trust deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,063.74 into trust to extend deadline one month from Sept 11 to Oct 11, 2024.","Funding from Scilex Holding (SCLX) convertible promissory note up to $180,000, zero interest.","Note convertible into DECA Class A shares at $10.00 per share upon business combination close.","Remaining $149,899.52 of note principal available to fund further monthly extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213664,"accession_number":"0001213900-24-075736","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Denali SPAC enters $2.5B stock merger with Semnur Pharmaceuticals","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Equity value of $2.5B; consideration payable in Denali (New Semnur) common shares.","Scilex (Semnur parent) buys 500k Denali Class B shares for $2M cash and 300k Scilex shares.","Closing targeted for Q1 2025; subject to shareholder vote, HSR clearance, Nasdaq listing.","Sponsor and directors commit to vote for deal; Scilex signs stockholder support agreement.","Post-closing, Denali renamed Semnur Pharma; Scilex gets board designation rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213663,"accession_number":"0001213900-24-067209","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to Sep 11 via $180K Scilex note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $15,036.74 into trust to extend deadline to Sep 11, 2024 from Aug 11.","Issued up to $180,000 convertible note to Scilex (SCLX); initial draw $15,036.74.","Note bears no interest, repayable upon business combination or liquidation; convertible at $10/share.","Remaining $164,963.26 available for future monthly extensions as needed.","If no business combination, note repaid only from non-trust funds or forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213662,"accession_number":"0001213900-24-062099","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. dismisses Marcum LLP, appoints Marcum Asia as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed Marcum LLP as independent auditor effective July 15, 2024, upon Audit Committee recommendation.","Marcum's reports for FY 2023 and 2022 had a going concern explanatory paragraph but no adverse opinion or disagreements.","Appointed Marcum Asia CPAs LLP as new independent auditor for the fiscal year ending December 31, 2024, effective July 15, 2024.","No reportable events or disagreements occurred during the prior two fiscal years and subsequent interim periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213661,"accession_number":"0001213900-24-060537","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.01","2.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Denali Capital shareholders approve extension to Apr 2025; 3.8M shares redeemed for ~$43.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved extension of business combination deadline from July 11, 2024 to April 11, 2025 via monthly extensions.","3,785,992 public shares redeemed at ~$11.47 per share, removing ~$43.4 million from trust account; only 751,837 public shares remain.","Sponsor issued a convertible promissory note of up to $180,000 to fund extension deposits; initial $15,063.74 deposited for one-month extension.","Note is convertible into Class A ordinary shares at $10.00 per share upon business combination; no interest accrues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213660,"accession_number":"0001213900-24-059541","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Denali Capital SPAC signs LOI to combine with Semnur Pharma at up to $2B valuation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-transaction equity value of Semnur up to $2.0B, subject to third-party fairness opinion adjustment.","Expected cash on hand at closing up to $40M depending on SPAC share redemptions.","Combined company to focus on SP-102 (SEMDEXA), a non-opioid epidural gel for sciatica with FDA Fast Track status.","Scilex Holding (Nasdaq: SCLX) expected to be majority holder of the combined company.","Parties anticipate seeking SPAC shareholder approval in second half of 2024; no definitive agreement yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232872,"accession_number":"0001213900-24-056571","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Denali Capital terminates business combination with Longevity Biomedical; SPAC seeks new target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger agreement terminated effective June 26, 2024, by mutual agreement of Denali and Longevity Biomedical.","Original merger agreement was entered January 25, 2023; no reason for termination specified.","Denali and its sponsor will pursue alternative initial business combination; S-4 registration to be withdrawn.","Ancillary agreements also automatically terminate; certain customary survival provisions remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251064,"accession_number":"0001213900-24-017542","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Denali Capital receives Nasdaq deficiency notice for MVLS below $50M; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Feb 22, 2024 cites MVLS below $50M for 30 consecutive days, violating Rule 5450(b)(2)(A).","Also flagged non-compliance with total assets/revenue test under Rule 5450(b)(3)(A).","Company has until Aug 20, 2024 to regain compliance by closing MVLS at or above $50M for 10 consecutive days.","If unable, may transfer to Nasdaq Capital Market or face delisting; appeal rights available.","Company will monitor MVLS and evaluate options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251063,"accession_number":"0001213900-24-002430","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Denali Capital shareholders approve merger with Longevity Biomedical; 4.44M shares redeemed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved all proposals: Business Combination, Merger, Share Capital, Organizational Documents, Governance, and Incentive Plan.","Approximately 4,440,202 public shares redeemed from trust account after withdrawals, ahead of closing.","Adjornment proposal not needed as sufficient votes secured for all other proposals.","Company plans to close the Business Combination as detailed in the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268653,"accession_number":"0001213900-23-099880","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital postpones extraordinary general meeting to Jan 9, extends redemption deadline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extraordinary general meeting moved from Jan 4 to Jan 9, 2024 at 9:00 AM ET.","Redemption request deadline extended to Jan 5, 2024 at 5:00 PM ET.","Meeting location unchanged; virtual attendance now also available via live webcast.","No change to record date (Dec 14, 2023) or proposals to be voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268652,"accession_number":"0001213900-23-088773","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Denali SPAC amends PIPE; cuts preferred shares to 1.3M, adds warrants, waives asset condition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FutureTech Capital reduced preferred stock commitment from 1.8M to 1.3M shares at $10 per share.","Each preferred share now includes two warrants exercisable at $8.00 for five years starting six months post-closing.","Underwriters agreed to take $866,250 deferred discount as 86,625 Holdco common shares; $2,021,250 remains cash.","Parties waived condition requiring Holdco to have net tangible assets of at least $5,000,001 at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268651,"accession_number":"0001013762-23-003253","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["1.01","2.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Denali Capital extension approved, ~$40.5M redeemed, up to $450k promissory note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved extension to July 11, 2024 with monthly $50k deposits; $50k deposited for first month.","Approx 3.7M public shares redeemed for $40.5M ($10.92/share); public float reduced to ~4.54M shares.","Issued convertible promissory note up to $450k to FutureTech Capital (initial $50k), convertible at $10/share upon business combination.","Also approved founder share early conversion and removal of $5M net tangible asset redemption limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285770,"accession_number":"0001213900-23-072288","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Longevity Biomedical waives $30M minimum cash condition for Denali merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Longevity irrevocably waived the $30M minimum cash condition in the merger agreement with Denali Capital Acquisition Corp.","Waiver effective August 29, 2023; removes a key closing condition for the business combination.","Merger agreement originally signed Jan 25, 2023, amended April 11, 2023.","Parties include Denali, Longevity, Holdco, Merger Subs, and seller representative Bradford A. Zakes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285769,"accession_number":"0001213900-23-071031","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Denali SPAC Holdco secures $18M Series A Preferred investment from FutureTech Capital for business combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FutureTech Capital commits to purchase 1.8M shares of Series A Convertible Preferred Stock at $10/share ($18M total).","Closing contingent on concurrent consummation of business combination with Longevity Biomedical.","Preferred stock convertible into common at lower of $8.00 or 80% of 20-day VWAP, with $5.00 floor conversion price.","Holders vote with common on as-converted basis and receive dividends as paid on common shares.","Post-combination entity expected to list on Nasdaq as LBIO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285768,"accession_number":"0001213900-23-063189","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Denali Capital files updated investor presentation for proposed merger with Longevity Biomedical","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Exhibit 99.1 is an August 2023 investor presentation for the business combination with Longevity Biomedical, superseding the January 2023 version.","The presentation will be used in meetings with investors; no specific new deal terms or financial projections are disclosed in the filing.","Upon closing, each of Denali and Longevity will become wholly-owned subsidiaries of Holdco, renamed Longevity Biomedical, Inc.","The transaction remains subject to regulatory and stockholder approvals; the registration statement was filed on March 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285767,"accession_number":"0001213900-23-056618","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to Oct 11, 2023 with $825K convertible note to FutureTech Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $825,000 into trust account to extend deadline by three months from July 11 to October 11, 2023.","Issued convertible promissory note for $825,000 to FutureTech Capital LLC; convertible into Class A shares at $10 per share upon business combination.","Interest at lowest short-term Applicable Federal Rate; note matures upon business combination or liquidation.","This is the second of two permissible three-month extensions under the company's governing documents.","If no business combination, note will be repaid only from funds outside trust account or forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305718,"accession_number":"0001575872-23-000548","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Denali Capital extends business combination deadline to July 11, 2023 with $825K trust deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $825,000 into trust account to extend deadline from April 11 to July 11, 2023; first of two permitted three-month extensions.","Issued convertible promissory note to sponsor for up to $825,000; initial $412,500 drawn, balance drawable; converts at $10 per share.","Amendment to merger agreement ensures repayment of note at closing does not reduce the minimum cash condition.","Business combination target is Longevity Biomedical, Inc.; merger agreement entered January 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325027,"accession_number":"0001575872-23-000144","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Denali Capital SPAC to merge with Longevity Biomedical in deal valued at $128M, listing as LBIO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration of $128M payable in shares of New PubCo common stock at $10.00 per share.","Combined company will be named Longevity Biomedical, Inc.; common stock expected to list on Nasdaq under ticker LBIO.","Transaction includes concurrent acquisitions of Cerevast Medical, Aegeria Soft Tissue, and Novokera by Longevity.","Sponsor (Denali Capital Global Investments) and largest Longevity stockholder entered voting/support agreements.","Closing conditions include at least $30M unrestricted cash proceeds remaining after redemptions and expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325026,"accession_number":"0001575872-23-000150","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K/A","filed_at":"2023-01-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. enters merger agreement with Longevity Biomedical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Denali entered into a merger agreement with Longevity Biomedical, Inc. on Jan 25, 2023, with a total enterprise value of $128 million.","Under the merger, Denali SPAC Holdco will become New PubCo, renamed Longevity Biomedical, expected to list on NASDAQ under ticker LBIO.","The transaction requires approval by Denali shareholders and other conditions, including net tangible assets of at least $5,000,001 after redemptions.","Sponsor and Investor FutureTech Capital agreed to purchase 625,000 Class B units for $5 million, with $2 million already paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342817,"accession_number":"0001575872-22-000992","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp replaces auditor; prior audit flagged going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Friedman LLP on Oct 14, 2022; appointed Marcum LLP effective immediately.","Auditor change follows Friedman's merger with Marcum on Sept 1, 2022; no disagreements or reportable events.","Friedman's prior audit report (Jan 5–Feb 7, 2022) noted going concern uncertainty.","Marcum engaged for fiscal year ending Dec 31, 2022; no prior consultations occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378221,"accession_number":"0001575872-22-000476","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. announces separate trading of Class A shares and warrants starting May 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Units from IPO of 8,250,000 units may be separated into Class A ordinary shares and warrants effective May 31, 2022.","Each unit consists of one Class A ordinary share and one redeemable warrant to purchase one Class A share at $11.50.","Separated shares trade under DECA and warrants under DECAW; units remain under DECAU on Nasdaq.","No fractional warrants will be issued; holders must contact transfer agent VStock Transfer to separate units.","Joint book-runners were US Tiger Securities, Inc. and EF Hutton; Craig-Hallum acted as qualified independent underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378220,"accession_number":"0001575872-22-000277","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. completes $82.5M IPO and $5.1M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 8,250,000 units at $10.00/unit raised $82.5M gross; private placement of 510,000 units to sponsor raised $5.1M.","Total $84.15M deposited into trust account for benefit of public shareholders; redemption value set at $10.20/share.","Company has 12 months (extendable to 18) to complete a business combination or will liquidate.","Each unit consists of one Class A share and one warrant exercisable at $11.50 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378219,"accession_number":"0001575872-22-000269","cik":1913577,"company_name":"Semnur Pharmaceuticals, Inc.","ticker":"SMNR","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.","Gross proceeds $82.5M from IPO and $5.1M from private placement of 510,000 units to sponsor.","Trust account funded with $84.15M; proceeds held until business combination or redemption.","Appoints Huifeng Chang, Jim Mao, Kevin D. Vassily as independent directors; board classified three classes.","Units (DECAU), Class A shares (DECA), and warrants (DECAW) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":690627411.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}